Scandinavian Journal of Pain最新文献

Objectives: A significant subset of patients with mental health disorders (MHDs) fail to respond to standard management and are termed as treatment-resistant. This cohort has limited options for managing their condition. Autonomic dysfunction has been reported in the neurobiology of MHDs including anxiety, depression, obsessive-compulsive disorder (OCD), panic disorder, and bipolar disorder (BD). Stellate ganglion block (SGB) is an emerging treatment that dampens sympathetic activity and has been shown to be of benefit in the management of post-traumatic stress disorder.

Methods: Patients with treatment-resistant disparate MHDs were reviewed by a multidisciplinary team comprising a psychiatrist, a clinical psychologist, and a pain medicine physician. Patients were offered SGB as a novel strategy in the management of treatment-resistant conditions. Validated outcome measures were completed at baseline, 4 weeks, and 16 weeks post-intervention.

Results: Four patients with heterogenous treatment-resistant MHDs who received SGB are presented in this report. SGB resulted in an improvement in BD, OCD with alcohol addiction, opioid addiction, and health anxiety.

Conclusion: SGB could have a role in the management of treatment-resistant MHDs.

Objective: The objective of this scoping review was to investigate the available literature on physical and quality of life (QoL) outcomes of underwater treadmill exercise trials in clinical chronic pain samples.

Methods: A scoping search of studies of the effectiveness of underwater treadmill exercise trials from 1947 to 2024 was conducted using the following databases: EMBASE, MEDLINE, SPORTDiscus, CINAHL, and Cochrane Reviews. To be included, studies were required to have included adult participants living with chronic pain (defined as pain lasting for 3 months or longer) who participated in an active underwater treadmill exercise intervention. No restrictions on pain diagnosis were applied. All clinical trials, including but not limited to randomized controlled trials (RCTs), feasibility trials, and pilot studies, were included in the search. Two independent reviewers determined whether studies met inclusion criteria, and a third reviewer resolved any disagreement on study inclusion.

Results: The initial search identified 2,209 studies: 314 articles were removed for duplications, 1,781 were removed because they did not meet inclusion criteria, and 113 were retained for full-text review. The full-text review yielded nine studies, all of which included samples consisting of participants with osteoarthritis. The following variables were investigated in the included studies to varying degrees: pain, QoL, mobility, balance, strength, and changes in gait kinematics. Multiple studies identified significant differences between control groups or pre-intervention groups and underwater treadmill groups or post-intervention groups in chronic pain, balance, mobility, strength, and QoL.

Conclusion: Findings suggest that underwater treadmill exercise leads to positive changes in chronic pain, balance, mobility, strength, and QoL. However, more studies, particularly RCTs with larger samples that include individuals with chronic pain conditions other than osteoarthritis, are warranted.

Objectives: The association between baseline laboratory parameters and experienced well-being in healthy individuals remains uncertain. This study explored the relationship between clinical laboratory profiles and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores for pain, stiffness, and physical functional limitation in healthy individuals in Qatar.

Methods: Clinical laboratory data were collected from 1,764 Qatar Biobank participants who also completed the WOMAC questionnaire: lipid profiles (high-density lipoprotein, low-density lipoprotein, cholesterol, and triglycerides), endocrine markers (TSH, T3, T4, estradiol, and testosterone), and two inflammatory markers (CRP and fibrinogen). Multiple linear regression was used with 11 clinical indicators as independent variables and the subscale and total WOMAC scores as dependent variables. Multivariate effects of each indicator on the outcomes were assessed, and univariate effects were examined when significant.

Results: Testosterone had a significant impact on all WOMAC subscales (pain, stiffness, and functional limitation) and the total WOMAC score. Higher testosterone levels were associated with a reduction in pain (β = -0.03, t = -3.505, p < 0.001, 95% CI = -0.052, -0.015), stiffness (β = -0.01, t = -2.265, p = 0.024, 95% CI = -0.018, -0.001), physical dysfunction (β = -0.08, t = -3.265, p = 0.001, 95% CI = -0.135, -0.034), and total WOMAC scores (β = -0.127, t = -3.444, p < 0.001, 95% CI = -0.199, -0.055). Elevated fibrinogen levels were associated with an increase in stiffness (β = 0.155, t = 2.241, p = 0.025, 95% CI = 0.019, 0.290), physical dysfunction (β = 1.17, t = 2.808, p = 0.005, 95% CI = 0.354, 1.997), and total WOMAC scores (β = 1.610, t = 2.691, p = 0.007, 95% CI = 0.437, 2.784).

Conclusion: Testosterone may protect against pain, stiffness, and physical dysfunction, while high fibrinogen levels might be a surrogate of systemic inflammation that enhances stiffness and limits physical function. Measuring multiple clinical and laboratory markers in healthy individuals may enhance our understanding of the molecular mechanisms underlying pain.

Objectives: Autonomic regulation has been identified as a potential regulator of pain via vagal nerve mediation, assessed through heart rate variability (HRV). Non-invasive vagal nerve stimulation (nVNS) and heart rate variability biofeedback (HRVB) have been proposed to modulate pain. A limited number of studies compare nVNS and HRVB in persons with chronic pain conditions. This systematic review compared interventions of nVNS and HRVB in adults with long-standing pain conditions.

Methods: PubMed, MEDLINE, CINAHL, SPORTDiscus, Google Scholar, and Cochrane library were used to retrieve the randomized controlled trials for this review between the years 2010 and 2023. Search terms included chronic pain, fibromyalgia, headache, migraine, vagus nerve stimulation, biofeedback, HRV, pain assessment, pain, and transcutaneous.

Results: Ten full-text articles of 1,474 identified were selected for full qualitative synthesis, with a combined population of 813 subjects. There were n = 763 subjects in studies of nVNS and n = 50 subjects for HRVB. Six of the nine nVNS studies looked at headache disorders and migraines (n = 603), with two investigating effects on fibromyalgia symptoms (n = 138) and one the effects on chronic low back pain (n = 22). Of the nVNS studies, three demonstrated significant results in episode frequency, six in pain intensity (PI) reduction, and three in reduced medication use. The HRVB study showed statistically significant findings for reduced PI, depression scores, and increased HRV coherence.

Conclusion: Moderate to high-quality evidence suggests that nVNS is beneficial in reducing headache frequency and is well-tolerated, indicating it might be an alternative intervention to medication. HRVB interventions are beneficial in reducing pain, depression scores, use of non-steroidal anti-inflammatory medication, and in increasing HRV coherence ratio. HRVB and nVNS appear to show clinical benefits for chronic pain conditions; however, insufficient literature exists to support either approach.

Objectives: The efficacy of long-term opioid therapy (LTOT) in treating patients with chronic non-cancer pain (CnCP) is questionable, and the potential risks of adverse effects are well established. The aims were as follows: (1) compare characteristics in patients exposed to LTOT vs non-exposed. (2) Regarding opioid-exposed patients, describe characteristics of patients with risk factors for opioid use disorder or overdose in relation to opioid dosage.

Method: A cross-sectional study was conducted at a Swedish tertiary pain rehabilitation clinic serving CnCP patients. The study population comprised 1,604 patients ≥18 years old registered in the Swedish Quality Registry for Pain Rehabilitation between 2018 and 2020. Data on dispensed opioids were extracted from the Swedish Prescribed Drug Register. Dependent variables were as follows: LTOT vs non-LTOT and exposed opioid dosage <50 mg morphine equivalent/day (MME/day) vs ≥50 MME/day.

Results: Of the included patients, 681 (42.5%) had at least one dispensation of opioids 180 days prior to assessment, 601 with a calculated opioid dosage ≥1 MME/day, and 424 (26.4%) were exposed to LTOT. The type of opioid prescribed was, in descending order, oxycodone (42.3% of all dispensations), codeine in combination with paracetamol (17.6%), tramadol (13.8%), and morphine (8.1%). A total of 89 cases had dosages of ≥50 MME/day and 430 patient dosages <50 MME/day. Patients exposed to LTOT exhibited an increased odds ratio (OR) of 2.685 (95% CI, 1.942-3.711) for concomitant use of benzodiazepines and male sex (OR, 1.694; 95% CI, 1.227-2.337). Patients receiving doses ≥50 MME/day were all, except one, exposed to LTOT. The concomitant use of benzodiazepines (OR 1.814, 95% CI 1.264-3.331) and male sex (OR, 1.777; 95% CI, 1.178-3.102) indicated a higher OR for opioid doses ≥50 MME/day.

Conclusions: LTOT strongly influenced the opioid dose. Furthermore, concomitant benzodiazepine dispensation and male sex were over-represented in patients exposed to LTOT as well as those exposed to opioid doses ≥50 MME/day.

Objectives: Music festivals are often a source of joy, but also a risk of injury. While previous studies suggest music can relieve pain, its effect has not been tested in festival settings, nor has the effect of high-energy vs soothing music been compared. We hypothesized that guests at a heavy metal music festival would experience less pain when listening to thrash heavy metal compared to relaxing music, with the effect being influenced by music preference and increased with higher alcohol intake.

Methods: This factorial randomized non-blinded crossover trial assessed pain during a 5°C cold pressor test (CPT) at a heavy metal festival. Participants were randomized to listen to either Slayer's "Raining Blood" or Enya's "Orinoco Flow" during their first CPT, and the opposite song during the second CPT. The primary outcome was pain during the CPT, assessed as area under the curve (AUC). Music fondness and breath alcohol concentration (BrAC) were measured before each CPT.

Results: Forty-five adults, aged 19-58 years, were included, and completed both CPTs. Significantly more pain was reported while listening to Enya (AUC 1,155 [IQR 588-1,507]) vs Slayer (AUC 975 [IQR 682-1,492]) (p = 0.048). Higher BrAC was associated with decreased pain (p = 0.042). Participants with higher fondness of Enya experienced significantly more pain than those who liked the song less (p = 0.021). Fondness of Slayer had no effect on pain perception (p = 0.7).

Conclusion: Listening to thrash heavy metal, specifically "Raining Blood" by Slayer during painful stimuli results in lower pain intensity than listening to relaxing music in the form of "Orinoco Flow" by Enya. The findings' impact on pain in a clinical setting should be explored.

Objectives: Since 2008, patients have had access to reimbursed analgesics, including opioids, for chronic pain in Norway. There is a need for knowledge on the occurrence and trends over time of substance use disorder (SUD) diagnoses among patients who receive reimbursed opioids for chronic pain. The primary aim of this study was to investigate the prevalence of SUD diagnoses in patients with chronic pain using reimbursed opioids from 2010 to 2019 in Norway. The secondary aim was to investigate the prevalence of other mental health diagnoses among those receiving reimbursed opioids in the subgroups with and without SUD diagnoses.

Methods: A cross-sectional design utilising data from four Norwegian nationwide registries.

Results: The annual number of individuals with SUD diagnoses increased from 377 to 932 from 2010 to 2019, while the annual prevalence of individuals with SUD remained relatively stable at around 5%. There was a higher prevalence for all categories of other mental health diagnoses among individuals with a SUD diagnosis, compared to those without a SUD diagnosis.

Conclusion: The prevalence of SUD diagnoses was low in the population using reimbursed opioids for chronic pain in Norway, but the number of patients increased in the study period because the number of individuals receiving reimbursed opioids increased. Patients with a SUD used on average twice the daily doses of opioids compared to patients without a SUD. They were also more likely to have an additional mental health diagnosis.

Objectives: There is an ongoing opioid crisis in the United States where the illicit and non-medical use of prescription opioids is associated with an increasing number of overdose deaths. Few studies have investigated opioid-induced effects on cell viability, and comparative studies are limited. Here, we examine the toxicity of six commonly used opioids: methadone, morphine, oxycodone, hydromorphone, ketobemidone, and fentanyl with respect to mitochondrial and membrane function in vitro.

Methods: The opioids were tested in four different cell cultures: primary cortical cell cultures, human neuroblastoma SH-SY5Y cells, and both differentiated and undifferentiated neuroblastoma/glioma hybrid NG108-15 cells. The mitochondrial activity was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and the membrane integrity was assessed by measuring the leakage of lactate dehydrogenase. To compare the different opioids, the toxic dose (TD₅₀) was calculated.

Results: The results displayed a similar trend of opioid-reduced cell viability in all four cell cultures. The most toxic opioid was methadone, followed by fentanyl, while morphine was overall ranked as the least toxic opioid displaying little to no negative impact on cell viability. The remaining opioids varied in rank between the different cell types.

Conclusion: This in vitro study highlights opioid-dependent variations in toxicity across all four tested cell types, with methadone emerging as the most potent opioid.